Evelo Biosciences Inc
NASDAQ:EVLO
Evelo Biosciences Inc
Total Liabilities
Evelo Biosciences Inc
Total Liabilities Peer Comparison
Competitive Total Liabilities Analysis
Latest Figures & CAGR of Competitors
Company | Total Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Evelo Biosciences Inc
NASDAQ:EVLO
|
Total Liabilities
$47.3m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
14%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Total Liabilities
$140.9B
|
CAGR 3-Years
1%
|
CAGR 5-Years
17%
|
CAGR 10-Years
19%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Liabilities
$38.8B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
10%
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Liabilities
$88B
|
CAGR 3-Years
18%
|
CAGR 5-Years
11%
|
CAGR 10-Years
7%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Liabilities
$5.4B
|
CAGR 3-Years
20%
|
CAGR 5-Years
24%
|
CAGR 10-Years
19%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Liabilities
$7.4B
|
CAGR 3-Years
8%
|
CAGR 5-Years
17%
|
CAGR 10-Years
22%
|
See Also
What is Evelo Biosciences Inc's Total Liabilities?
Total Liabilities
47.3m
USD
Based on the financial report for Sep 30, 2023, Evelo Biosciences Inc's Total Liabilities amounts to 47.3m USD.
What is Evelo Biosciences Inc's Total Liabilities growth rate?
Total Liabilities CAGR 5Y
14%
Over the last year, the Total Liabilities growth was -39%. The average annual Total Liabilities growth rates for Evelo Biosciences Inc have been -5% over the past three years , 14% over the past five years .